VOR BIOPHARMA INC VOR
COM NEW · Common Stock · CUSIP 929033207
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersBoston, MA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $13.00. Options: 6 managers hold calls ($16.2m notional), 4 hold puts ($5.9m).
Trends to Q4 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2025 | 1 |
| Q2 2025 | 1 |
| Q3 2025 | 36 |
| Q4 2025 | 55 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q2 2025 | 0 | 0 |
| Q3 2025 | 36 | 1 |
| Q4 2025 | 47 | 12 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q1 2025 | $0 | $0 | — |
| Q2 2025 | $0 | $0 | — |
| Q3 2025 | $360.9m | $57.8m | 0.16 |
| Q4 2025 | $16.2m | $5.9m | 0.37 |
Biggest buyers
| RA CAPITAL MANAGEMENT, L.P. | Added | +3.4m |
| FCPM III SERVICES B.V. | Added | +3.2m |
| Frazier Life Sciences Management, L.P. | New | +2.5m |
| FMR LLC | Added | +2.3m |
| Paradigm Biocapital Advisors LP | New | +1.8m |
| Venrock Adviser, LLC | Added | +1.4m |
| GREAT POINT PARTNERS LLC | New | +1.4m |
| Caligan Partners LP | New | +925.1k |
| VANGUARD GROUP INC | Added | +665.1k |
| BlackRock, Inc. | Added | +431.1k |
Biggest sellers
| Ariose Capital Management Ltd | Sold out | -110.2k |
| TANG CAPITAL MANAGEMENT LLC | Sold out | -50.0k |
| Woodline Partners LP | Sold out | -27.4k |
| Polymer Capital Management (HK) LTD | Sold out | -21.2k |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -14.6k |
| Virtu Financial LLC | Sold out | -8.1k |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | Sold out | -6.2k |
| Scientech Research LLC | Sold out | -6.1k |
| BNP PARIBAS FINANCIAL MARKETS | Reduced | -5.8k |
| Trustees of Columbia University in the City of New York | Sold out | -4.6k |
Biggest calls
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Reduced | $13.1m999.3k shares |
| GROUP ONE TRADING LLC | Reduced | $2.4m185.0k shares |
| Hudson Bay Capital Management LP | Unchanged | $277.9k21.2k shares |
| CITADEL ADVISORS LLC | Added | $211.4k16.2k shares |
| JANE STREET GROUP, LLC | Reduced | $173.0k13.2k shares |
| Belvedere Trading LLC | Reduced | $37.3k57.4k shares |
Biggest puts
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Reduced | $4.7m355.9k shares |
| GROUP ONE TRADING LLC | Reduced | $1.1m85.0k shares |
| CITADEL ADVISORS LLC | Added | $166.4k12.7k shares |
| Belvedere Trading LLC | Reduced | $130200 shares |
Options at notional value: the value of the shares the contracts control, as filers report them, not what the options cost. Not included in the holders, shares or buying above.
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
RA CAPITAL MANAGEMENT, L.P.
13D · may seek influence
no change · filed 2026-07-21
Stated purposeItem 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer. Full filing |
19.9% |
Reprogrammed Interchange LLC
13D · may seek influence
filed 2025-10-17
Stated purposeItem 4 of Schedule 13D is hereby amended and supplemented as follows: From October 15, 2025 through October 16, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer. 1. 71,655 shares on October 15, 2025, at a weighted average per share sale price of $31.9196. 2. 2,021 shares on October 16, 2025, at a weighted average per share sale price of $30.4548. Full filing |
17.6% |
| FMR LLC 13G · institution +2.9 pts · filed 2026-08-07 | 12.0% |
| TCG Crossover GP II, LLC 13G · passive investor new · filed 2026-04-01 | 10.5% |
ForGrowth III PA B.V.
13D · may seek influence
no change · filed 2025-12-23
Stated purposeThe Reporting Persons acquired their shares of Common Stock as an investment in the ordinary course of business. On December 18, 2025, Wouter Joustra, a General Partner at Forbion Capital, was appointed to the Issuer's board of directors. The Reporting Persons, either directly or indirectly through Mr. Joustra, may engage in discussions from time to time with the Issuer's board of directors, the Issuer's management or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing of the shares or other securities of the Issuer; (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) t… Full filing |
10.0% |
| Venrock Healthcare Capital Partners III, L.P. 13G · passive investor no change · filed 2026-08-14 | 9.9% |
| Verve Capital Ltd 13G · passive investor -3.0 pts · filed 2026-08-13 | 6.3% |
| BlackRock, Inc. 13G · institution new · filed 2026-07-30 | 5.7% |
Fell to 5% or below in the last year: Frazier Life Sciences Public Fund, L.P. (4.2%, 2026-08-14), Qiming Venture Partners VIII-HC, L.P. (2.0%, 2026-05-06), GREAT POINT PARTNERS LLC (3.3%, 2026-02-17), Paradigm Biocapital Advisors LP (4.5%, 2026-02-17)
Insider purchases and sales in Q4 2025
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q1 2024 | 0 | — | 0 | — | — |
| Q2 2024 | 0 | — | 1 | $20.4k | $20.4k |
| Q3 2024 | 0 | — | 0 | — | — |
| Q4 2024 | 0 | — | 1 | $12.9k | $12.9k |
| Q1 2025 | 0 | — | 1 | $6.7k | $6.7k |
| Q2 2025 | 0 | — | 0 | — | — |
| Q3 2025 | 0 | — | 0 | — | — |
| Q4 2025 | 0 | — | 1 | $33.7m | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2025-10-30 | RA Capital Healthcare Fund LP +3 Director · See footnotes | Sold | $617.4k24.6k shares |
| 2025-10-29 | RA Capital Healthcare Fund LP +3 Director · See footnotes | Sold | $6.3m251.5k shares |
| 2025-10-28 | RA Capital Healthcare Fund LP +3 Director · See footnotes | Sold | $3.4m124.3k shares |
| 2025-10-27 | RA Capital Healthcare Fund LP +3 Director · See footnotes | Sold | $2.6m90.9k shares |
| 2025-10-24 | RA Capital Healthcare Fund LP +3 Director · See footnotes | Sold | $1.5m53.3k shares |
| 2025-10-23 | RA Capital Healthcare Fund LP +3 Director · See footnotes | Sold | $2.2m76.9k shares |
| 2025-10-21 | RA Capital Healthcare Fund LP +4 Director · See footnotes | Sold | $703.5k25.0k shares |
| 2025-10-21 | Hoffman Reid +1 10% owner | Sold | $6.0k200 shares |
| 2025-10-20 | RA Capital Healthcare Fund LP +4 Director · See footnotes | Sold | $2.7m92.0k shares |
| 2025-10-20 | Hoffman Reid +1 10% owner | Sold | $349.1k11.6k shares |
| 2025-10-17 | RA Capital Healthcare Fund LP +4 Director · See footnotes | Sold | $7.7m260.9k shares |
| 2025-10-17 | Hoffman Reid +1 10% owner | Sold | $778.0k25.7k shares |
| 2025-10-16 | RA Capital Healthcare Fund LP +4 Director · See footnotes | Sold | $4.5m151.8k shares |
| 2025-10-16 | Hoffman Reid +1 10% owner | Sold | $61.5k2.0k shares |
| 2025-10-15 | Hoffman Reid +1 10% owner | Sold | $2.3m71.7k shares |
| 2025-10-15 | RA Capital Healthcare Fund LP +4 Director · See footnotes | Sold | $1.6m51.4k shares |
| 2025-10-14 | Hoffman Reid +1 10% owner | Sold | $1.0m33.7k shares |
| 2025-10-13 | Hoffman Reid +1 10% owner | Sold | $713.8k22.0k shares |
| 2025-10-10 | Hoffman Reid +1 10% owner | Sold | $1.3m41.0k shares |
| 2025-10-09 | Hoffman Reid +1 10% owner | Sold | $1.6m48.9k shares |
| 2025-10-08 | Hoffman Reid +1 10% owner | Sold | $2.5m75.3k shares |
| 2025-10-07 | Hoffman Reid +1 10% owner | Sold | $934.8k27.6k shares |
| 2025-10-06 | Hoffman Reid +1 10% owner | Sold | $2.6m70.8k shares |
| 2025-10-03 | Hoffman Reid +1 10% owner | Sold | $298.9k7.9k shares |
| 2025-10-02 | Hoffman Reid +1 10% owner | Sold | $1.3m32.5k shares |
| 2025-10-01 | Hoffman Reid +1 10% owner | Sold | $54.9k1.4k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q4 2025
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. 0.72% of their portfolio | 5.4m $70.7m | Added +3.4m |
| FCPM III SERVICES B.V. 6.20% of their portfolio | 3.6m $47.3m | Added +3.2m |
| Frazier Life Sciences Management, L.P. 0.89% of their portfolio | 2.5m $33.3m | New |
| FMR LLC 0.00% of their portfolio | 2.5m $33.0m | Added +2.3m |
| Venrock Adviser, LLC 1.26% of their portfolio | 1.9m $25.4m | Added +1.4m |
| Paradigm Biocapital Advisors LP 0.61% of their portfolio | 1.8m $22.9m | New |
| GREAT POINT PARTNERS LLC 5.81% of their portfolio | 1.4m $17.9m | New |
| NEXTBio Capital Management LP 7.67% of their portfolio | 1,000.0k $13.1m | First filing |
| Caligan Partners LP 0.91% of their portfolio | 925.1k $10.0m | New |
| VANGUARD GROUP INC 0.00% of their portfolio | 770.2k $10.1m | Added +665.1k |
| BlackRock, Inc. 0.00% of their portfolio | 465.6k $6.1m | Added +431.1k |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 433.9k $5.7m | Added +428.2k |
| SPHERA FUNDS MANAGEMENT LTD. 1.12% of their portfolio | 410.4k $5.4m | New |
| Laurion Capital Management LP 0.28% of their portfolio | 317.2k $4.1m | New |
| UBS Group AG 0.00% of their portfolio | 292.1k $3.8m | Added +216.2k |
| FINDELL CAPITAL MANAGEMENT LLC 1.00% of their portfolio | 231.0k $3.0m | New |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 224.5k $2.9m | Added +199.8k |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 185.8k $2.4m | Added +158.4k |
| TUDOR INVESTMENT CORP ET AL 0.01% of their portfolio | 167.7k $2.2m | New |
| AMERIPRISE FINANCIAL INC 0.00% of their portfolio | 163.1k $2.1m | New |
| GOLDMAN SACHS GROUP INC 0.00% of their portfolio | 145.6k $1.9m | Added +129.9k |
| Logos Global Management LP 0.09% of their portfolio | 100.0k $1.3m | New |
| JANE STREET GROUP, LLC 0.00% of their portfolio | 91.8k $1.2m | Added +75.1k |
| STATE STREET CORP 0.00% of their portfolio | 91.1k $1.2m | Added +82.0k |
| JOHNSON & JOHNSON 0.13% of their portfolio | 53.7k $702.8k | New |
| NORTHERN TRUST CORP 0.00% of their portfolio | 38.9k $509.4k | New |
| MORGAN STANLEY 0.00% of their portfolio | 28.5k $372.3k | Added +24.0k |
| Engineers Gate Manager LP 0.00% of their portfolio | 28.2k $368.9k | New |
| Quadrature Capital Ltd 0.00% of their portfolio | 26.8k $350.4k | New |
| Sarissa Capital Management LP 0.15% of their portfolio | 25.4k $332.2k | Unchanged |
| Bollard Group LLC 0.01% of their portfolio | 24.0k $314.0k | Added +21.2k |
| OMERS ADMINISTRATION Corp 0.00% of their portfolio | 20.7k $270.8k | New |
| Squarepoint Ops LLC 0.00% of their portfolio | 18.5k $241.4k | Added +13.7k |
| XTX Topco Ltd 0.01% of their portfolio | 17.5k $229.4k | New |
| INDEPENDENT FINANCIAL GROUP, LLC 0.00% of their portfolio | 17.0k $222.4k | New |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.00% of their portfolio | 14.8k $193.8k | New |
| Persistent Asset Partners Ltd 0.07% of their portfolio | 10.8k $141.2k | New |
| Shay Capital LLC 0.02% of their portfolio | 10.7k $140.5k | New |
| Susquehanna Portfolio Strategies, LLC 0.00% of their portfolio | 10.2k $133.5k | New |
| Chung Wu Investment Group, LLC 0.09% of their portfolio | 8.3k $108.6k | New |
| CITIGROUP INC 0.00% of their portfolio | 6.3k $82.9k | New |
| Hudson Bay Capital Management LP 0.00% of their portfolio | 5.1k $66.8k | New |
| China Universal Asset Management Co., Ltd. 0.00% of their portfolio | 2.7k $35.9k | New |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 2.3k $30.2k | Added +2.2k |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 1.7k $22.6k | Added +1.7k |
| BARCLAYS PLC 0.00% of their portfolio | 1.4k $18.3k | New |
| Mirae Asset Global Investments Co., Ltd. 0.00% of their portfolio | 819 $10.7k | New |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 396 $5.2k | Reduced -4.4k |
| GF FUND MANAGEMENT CO. LTD. 0.00% of their portfolio | 330 $4.3k | New |
| BNP PARIBAS FINANCIAL MARKETS 0.00% of their portfolio | 291 $3.8k | Reduced -5.8k |
| MAI Capital Management 0.00% of their portfolio | 40 $524 | Unchanged |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 7 $0 | Added +5 |
| Allworth Financial LP 0.00% of their portfolio | 3 $40 | Unchanged |
| SBI Securities Co., Ltd. 0.00% of their portfolio | 3 $39 | Unchanged |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 1 $13 | Unchanged |